Sex and Gender Differences in Rilpivirine based ART - Data from the HIVCENTER Frankfurt.

OBJECTIVES While Rilpivirine has shown high overall response rates in treatment-naïve patients without sex and gender specific differences in clinical trials, Sex and gender specific data in treatment experienced patients receiving rilpivirine are still limited. We conducted a 48 week efficacy and safety analysis in naïve and treatment experienced men and women using retrospective data from the HIVCENTER Frankfurt. MATERIALS AND METHODS In this retrospective observational study data of all patients who received a rilpivirine based regimen at the HIVCENTER between March 2011 and December 2015 were analyzed. Primary endpoint was the proportion of patients with any discontinuation until week 48. Virologic response rates (FDA snapshot analysis; HIV-1 RNA <50 copies/mL) were assessed at week 48. RESULTS 194 patients (34% female) were included in the analysis. 74% were treatment-experienced and 26% naïve, respectively. Discontinuations were observed in 31 (15.9%) patients. Regarding sex differences the proportion of discontinuations was significantly higher in women than in men (24.2% vs. 11.7%; p=0.024; ODDS-Ratio = 2.41; CI 1.12 - 5.18). Virologic failure occurred in 8 PLWHIV (4.1%). CONCLUSIONS While virologic overall response rates to rilpivirine based ART were high for both treatment-experienced and -naïve patients the proportion of discontinuations was significantly higher in women (24.2% vs. 11.7%; p = 0.024; ODDS-Ratio = 2.41; CI 1.12 - 5.18). Although the total number of patients with virologic failure was low (4.1%), the higher rate of ART discontinuations in female patients receiving RPV require close monitoring in the first months of treatment addressing special needs of women living with HIV.

[1]  L. Calza,et al.  Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project , 2018, Infection and drug resistance.

[2]  M. Battegay,et al.  Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study , 2017, BMC Infectious Diseases.

[3]  C. Katlama,et al.  Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study , 2017, HIV medicine.

[4]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[5]  K. White,et al.  Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults , 2014, AIDS.

[6]  B. Clotet,et al.  Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment‐naïve, HIV‐1‐infected patients at 48 weeks , 2013, HIV medicine.

[7]  W. Short,et al.  Effect of gender and race on the week 48 findings in treatment‐naïve, HIV‐1‐infected patients enrolled in the randomized, phase III trials ECHO and THRIVE , 2012, HIV medicine.

[8]  J. Mrus,et al.  Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience. , 2012, AIDS research and human retroviruses.

[9]  B. Clotet,et al.  Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials , 2012, Journal of acquired immune deficiency syndromes.

[10]  M. Johnson,et al.  Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study , 2010, The Journal of antimicrobial chemotherapy.

[11]  K. Squires,et al.  Sex-Based Outcomes of Darunavir–Ritonavir Therapy , 2010, Annals of Internal Medicine.

[12]  K. Ruxrungtham,et al.  Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial , 2010, AIDS.

[13]  A. Phillips,et al.  Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. , 2008, The Journal of infectious diseases.

[14]  C. Sabin,et al.  Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive Patients: The Role of Gender , 2007, Journal of acquired immune deficiency syndromes.

[15]  M. Kurowski,et al.  A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. , 2006, British journal of clinical pharmacology.

[16]  M. Lederman,et al.  Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  D. Mayers,et al.  Appropriate use of nevirapine for long-term therapy. , 2005, The Journal of infectious diseases.

[18]  R. Johann-Liang,et al.  Hepatotoxicity associated with nevirapine use. , 2004, Journal of acquired immune deficiency syndromes.

[19]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.